Earnings ·
Evolus Reports Q3 Net Revenue of $78.0M, Up 13% Year-Over-Year
EOLSEvolus, Inc.
Evolus reported third-quarter net revenue of $78.0 million, a 13% increase from the prior year, driven by double-digit growth in global toxin sales and expanding contributions from its hyaluronic acid gel portfolio. The company posted a GAAP operating loss of $8.4 million but delivered positive Adjusted EBITDA of $1.2 million, marking the fourth consecutive quarter of profitability on this metric. Evolus reaffirmed its full-year 2026 revenue guidance of $330 million to $337 million and updated non-GAAP operating expense expectations downward. The company also highlighted strong commercial execution, including over 1.6 million loyalty program members and continued inventory buildup ahead of potential tariffs. Evolus operates in the aesthetic injectables industry, developing and marketing neurotoxins and hyaluronic acid fillers.